Numerous studies have linked controlled psychedelics to improvements in mental health conditions such as depression and PTSD. In March, the FDA approved Esketamine as a treatment for depression. However, with much stigma surrounding psychedelics, researchers question how many patients would take psychedelic medications if prescribed to them. According to a new study, 40% of people with no experience of psychedelics would be unlikely to take the prescription due to fears of 'brain damage' or a 'bad trip'.
A new study clarifies the mechanism behind how ketamine works as an antidepressant. Researchers say there is evidence to suggest ketamine binds to NMDA receptors, instead of opioid receptors. Reducing the belief that ketamine is an opioid may make patients with depression more open to using the treatment.
Ketamine, an anesthetics which has been commonly used as an illicit party drug, is helping people overcome depression. The drug works rapidly and provides lasting relief from depressive symptoms for weeks after exposure. Researchers are examining how ketamine works in the brain to help positively influence behavior in those with mood disorders.
Researchers have found a diverse array of illicit drugs, including cocaine and ketamine, along with pesticides and pharmaceutical chemicals in British freshwater shrimp. While the concentrations of chemicals were considered low, researchers state there is a concern for the potential environmental risk this may pose to wildlife.
NV-5138, a small molecule drug that mimics the action of ketamine, provides fast-acting antidepressant responses in rodent models of depression. The drug is currently undergoing Phase 1 testing in humans.
The formation of prefrontal cortex dendritic spine formation sustains the remission of depressive related symptoms and behaviors following ketamine treatment by restoring lost spines.
The mGlu2 receptor plays a critical role in the effectiveness of ketamine for treating depression.
A new study reveals the combination of ketamine with naltrexone can help treat symptoms of both depression and addiction.
A new study reveals a brain region that contributes to anhedonia, the loss of pleasure, in those with depression. The study also shows how ketamine acts on this brain region, explaining why the drug appears to be so effective at treating anhedonia.
Researchers report ketamine's antidepressive effects require activation of opioid receptors in the brain. The study highlights the interaction between depression, pain and opioid addiction.